Connect Biopharma is trading 5.74% up at $2.02 as investors continue positioning ahead of expected topline results from its Phase 2 Seabreeze STAT asthma study.
- Early-September 2026 data were previously expected, making the pending readout the clearest catalyst.
- Major U.S. indices are lower on September 9, 2026, suggesting company-specific expectations are outweighing weak market sentiment.
- No new same-day company announcement was found.